세계의 불면증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the global Insomnia Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Insomnia Treatment Market Size (2025E): US$ 3.1 Billion
• Projected Market Value (2032F): US$ 4.2 Billion
• Global Market Growth Rate (CAGR 2025 to 2032): 4.60%

Insomnia Treatment Market - Report Scope:

The global insomnia treatment market comprises various therapeutic solutions aimed at alleviating insomnia, including pharmacological treatments, over-the-counter (OTC) medications, and cognitive behavioral therapies (CBT-I). The market is primarily driven by the rising prevalence of insomnia, a growing geriatric population, and increasing demand for effective and affordable treatments. Additionally, innovation in treatment options and an expanding undiagnosed patient pool are shaping the future of the insomnia treatment market.

Market Drivers:

The market growth of insomnia treatment is propelled by several key factors. Firstly, the increasing number of people suffering from insomnia, including those with undiagnosed conditions, creates an urgent demand for treatment. Additionally, the aging global population, especially individuals over 60, is more prone to sleep disorders, further driving demand for OTC sleep aids. OTC medications such as melatonin and Unisom sleep gel dominate the market due to their minimal side effects, with these products expected to capture the largest share of market revenue through 2026. Furthermore, pharmaceutical companies are investing heavily in research and development to discover new pharmacological treatments, expanding the variety of options available to patients.

Market Restraints:

Despite the promising growth prospects, the insomnia treatment market faces several challenges. One significant restraint is the high cost associated with research and development for new therapies. Moreover, regulatory barriers can slow down the introduction of new treatments, especially in emerging markets. Additionally, the complexity and variability of insomnia diagnoses can result in delayed or misdiagnosed cases, limiting the effectiveness of some therapeutic interventions. Furthermore, the availability of alternative treatments, such as behavioral therapies, may limit the demand for pharmacological solutions in certain markets.

Market Opportunities:

The growing recognition of undiagnosed insomnia presents a significant opportunity for market players. The expanding patient base in emerging economies, such as China and India, further opens up new avenues for growth. The rising interest in cognitive behavioral therapy (CBT-I) and other non-pharmacological treatments is expected to complement pharmacological solutions. Additionally, with millions spending on sleep aids, the burgeoning sleep-health economy represents a multi-billion-dollar market opportunity for pharmaceutical companies, health service providers, and retailers. The increasing focus on personalized medicine and innovative drug delivery mechanisms enhances patient compliance, creating further growth potential.

Key Questions Answered in the Report:

• What are the primary factors driving the global growth of the insomnia treatment market?
• How does the increasing geriatric population contribute to market expansion?
• What are the emerging trends and future projections for the global insomnia treatment market?
• How are pharmaceutical companies innovating in the insomnia treatment space?
• Who are the key players in the insomnia treatment market, and what strategies are they employing to stay competitive?

Competitive Intelligence and Business Strategy:

Leading companies in the insomnia treatment market, such as Pfizer Inc., Sanofi, and Merck & Co., are focusing on clinical research, product innovation, and expanding their portfolios to maintain a competitive edge. These companies are leveraging partnerships and collaborations to speed up the development of new insomnia therapies. Furthermore, advancements in drug delivery technologies, including oral capsules and targeted formulations, are helping to improve patient compliance and overall treatment effectiveness. These strategies aim to cater to the growing demand for effective insomnia solutions, especially in the face of an expanding, diverse global patient pool.

Key Companies Profiled:

• Sunovion Pharmaceuticals, Inc.
• Natrol, LLC
• GlaxoSmithKline Plc.
• Sanofi SA
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Mallinckrodt
• PERNIX Therapeutics
• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• Others.

Insomnia Treatment Market Segmentation:

By Drug Type:

• OTC Drugs
• Prescription Drugs

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• e commerce
• Drug Stores
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific excluding China (APEC)
• China
• Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Market Overview
• 1.2. Market Analysis
• 1.3. PMR Analysis and Recommendations
• 1.4. Wheel of Fortune

2. Market Introduction

• 2.1. Market Definition
• 2.2. Market Taxonomy
• 2.3. Inclusion and Exclusion

3. Market Dynamics

• 3.1. Macro-Economic Factors
• 3.2. Drivers
• 3.3. Restraints
• 3.4. Opportunity Analysis
• 3.5. Trends

4. Macroeconomic Assumptions

5. Global Economic Outlook

• 5.1. Gross Domestic Product by Region & Country, 2025 - 2032
• 5.2. Healthcare Sector Outlook
• 5.3. Healthcare Indicators

6. Key Inclusions

• 6.1. Epidemiology of Insomnia, By Region

7. North America Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

• 7.1. Introduction
• 7.2. Regional Market Trends
• 7.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
  • 7.3.1. U.S.
  • 7.3.2. Canada
• 7.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
• 7.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
  • 7.5.1. OTC Drugs
    • 7.5.1.1. OTC Sleep Aids
    • 7.5.1.2. OTC Sleep Supplements
  • 7.5.2. Prescription Drugs
• 7.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
• 7.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
  • 7.7.1. Hospital Pharmacies
  • 7.7.2. Retail Pharmacies
  • 7.7.3. e commerce
  • 7.7.4. Drug Stores
  • 7.7.5. Others
• 7.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
• 7.9. Market Attractiveness Analysis
  • 7.9.1. By Country
  • 7.9.2. By Drug Type
  • 7.9.3. By Distribution Channel

8. Latin America Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

• 8.1. Introduction
• 8.2. Regional Market Trends
• 8.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
  • 8.3.1. Argentina
  • 8.3.2. Brazil
  • 8.3.3. Mexico
  • 8.3.4. Rest of Latin America
• 8.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
• 8.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
  • 8.5.1. OTC Drugs
    • 8.5.1.1. OTC Sleep Aids
    • 8.5.1.2. OTC Sleep Supplements
  • 8.5.2. Prescription Drugs
• 8.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
• 8.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
  • 8.7.1. Hospital Pharmacies
  • 8.7.2. Retail Pharmacies
  • 8.7.3. e commerce
  • 8.7.4. Drug Stores
  • 8.7.5. Others
• 8.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
• 8.9. Market Attractiveness Analysis
  • 8.9.1. By Country
  • 8.9.2. By Drug Type
  • 8.9.3. By Distribution Channel

9. Europe Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

• 9.1. Introduction
• 9.2. Regional Market Trends
• 9.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
  • 9.3.1. Germany
  • 9.3.2. U.K.
  • 9.3.3. France
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Russia
  • 9.3.7. Poland
  • 9.3.8. Rest of Europe
• 9.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
• 9.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
  • 9.5.1. OTC Drugs
    • 9.5.1.1. OTC Sleep Aids
    • 9.5.1.2. OTC Sleep Supplements
  • 9.5.2. Prescription Drugs
• 9.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
• 9.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Retail Pharmacies
  • 9.7.3. e commerce
  • 9.7.4. Drug Stores
  • 9.7.5. Others
• 9.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
• 9.9. Market Attractiveness Analysis
  • 9.9.1. By Country
  • 9.9.2. By Drug Type
  • 9.9.3. By Distribution Channel

10. Asia Pacific Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

• 10.1. Introduction
• 10.2. Regional Market Trends
• 10.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia and New Zealand
  • 10.3.5. ASEAN
  • 10.3.6. Rest of Asia Pacific
• 10.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
• 10.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
  • 10.5.1. OTC Drugs
    • 10.5.1.1. OTC Sleep Aids
    • 10.5.1.2. OTC Sleep Supplements
  • 10.5.2. Prescription Drugs
• 10.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
• 10.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
  • 10.7.1. Hospital Pharmacies
  • 10.7.2. Retail Pharmacies
  • 10.7.3. e commerce
  • 10.7.4. Drug Stores
  • 10.7.5. Others
• 10.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
• 10.9. Market Attractiveness Analysis
  • 10.9.1. By Country
  • 10.9.2. By Drug Type
  • 10.9.3. By Distribution Channel

11. Middle East & Africa Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

• 11.1. Introduction
• 11.2. Key Regulations
• 11.3. Historical Market Size (US$ Bn) Trend Analysis By Country, 2020 - 2024
  • 11.3.1. GCC Countries
  • 11.3.2. South Africa
  • 11.3.3. Rest of MEA
• 11.4. Market Size (US$ Bn) Forecast By Country, 2025 - 2032
• 11.5. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
  • 11.5.1. OTC Drugs
    • 11.5.1.1. OTC Sleep Aids
    • 11.5.1.2. OTC Sleep Supplements
  • 11.5.2. Prescription Drugs
• 11.6. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
• 11.7. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
  • 11.7.1. Hospital Pharmacies
  • 11.7.2. Retail Pharmacies
  • 11.7.3. e commerce
  • 11.7.4. Drug Stores
  • 11.7.5. Others
• 11.8. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
• 11.9. Market Attractiveness Analysis
  • 11.9.1. By Country
  • 11.9.2. By Drug Type
  • 11.9.3. By Distribution Channel

12. Forecast Factors: Relevance and Impact

13. Competition Analysis

• 13.1. Competition Dashboard
• 13.2. Competition Benchmarking
• 13.3. Profitability and Gross Margin Analysis By Competition
• 13.4. Company Deep Dive
  • 13.4.1. Merck & Co. Inc.
    • 13.4.1.1. Overview
    • 13.4.1.2. Product and Technology Portfolio
    • 13.4.1.3. Production Footprint
    • 13.4.1.4. Sales Footprint
    • 13.4.1.5. Channel Footprint
    • 13.4.1.6. Strategy
      • 13.4.1.6.1. Marketing Strategy
      • 13.4.1.6.2. Product Strategy
      • 13.4.1.6.3. Channel Strategy
  • 13.4.2. Natrol, LLC
    • 13.4.2.1. Overview
    • 13.4.2.2. Product and Technology Portfolio
    • 13.4.2.3. Production Footprint
    • 13.4.2.4. Sales Footprint
    • 13.4.2.5. Channel Footprint
    • 13.4.2.6. Strategy
      • 13.4.2.6.1. Marketing Strategy
      • 13.4.2.6.2. Product Strategy
      • 13.4.2.6.3. Channel Strategy
  • 13.4.3. GlaxoSmithKline Plc.
    • 13.4.3.1. Overview
    • 13.4.3.2. Product and Technology Portfolio
    • 13.4.3.3. Production Footprint
    • 13.4.3.4. Sales Footprint
    • 13.4.3.5. Channel Footprint
    • 13.4.3.6. Strategy
      • 13.4.3.6.1. Marketing Strategy
      • 13.4.3.6.2. Product Strategy
      • 13.4.3.6.3. Channel Strategy
  • 13.4.4. Sanofi SA
    • 13.4.4.1. Overview
    • 13.4.4.2. Product and Technology Portfolio
    • 13.4.4.3. Production Footprint
    • 13.4.4.4. Sales Footprint
    • 13.4.4.5. Channel Footprint
    • 13.4.4.6. Strategy
      • 13.4.4.6.1. Marketing Strategy
      • 13.4.4.6.2. Product Strategy
      • 13.4.4.6.3. Channel Strategy
  • 13.4.5. Pfizer Inc.
    • 13.4.5.1. Overview
    • 13.4.5.2. Product and Technology Portfolio
    • 13.4.5.3. Production Footprint
    • 13.4.5.4. Sales Footprint
    • 13.4.5.5. Channel Footprint
    • 13.4.5.6. Strategy
      • 13.4.5.6.1. Marketing Strategy
      • 13.4.5.6.2. Product Strategy
      • 13.4.5.6.3. Channel Strategy
  • 13.4.6. Boehringer Ingelheim International GmbH
    • 13.4.6.1. Overview
    • 13.4.6.2. Product and Technology Portfolio
    • 13.4.6.3. Production Footprint
    • 13.4.6.4. Sales Footprint
    • 13.4.6.5. Channel Footprint
    • 13.4.6.6. Strategy
      • 13.4.6.6.1. Marketing Strategy
      • 13.4.6.6.2. Product Strategy
      • 13.4.6.6.3. Channel Strategy
  • 13.4.7. Mallinckrodt
    • 13.4.7.1. Overview
    • 13.4.7.2. Product and Technology Portfolio
    • 13.4.7.3. Production Footprint
    • 13.4.7.4. Sales Footprint
    • 13.4.7.5. Channel Footprint
    • 13.4.7.6. Strategy
      • 13.4.7.6.1. Marketing Strategy
      • 13.4.7.6.2. Product Strategy
      • 13.4.7.6.3. Channel Strategy
  • 13.4.8. PERNIX Therapeutics
    • 13.4.8.1. Overview
    • 13.4.8.2. Product and Technology Portfolio
    • 13.4.8.3. Production Footprint
    • 13.4.8.4. Sales Footprint
    • 13.4.8.5. Channel Footprint
    • 13.4.8.6. Strategy
      • 13.4.8.6.1. Marketing Strategy
      • 13.4.8.6.2. Product Strategy
      • 13.4.8.6.3. Channel Strategy
  • 13.4.9. Takeda Pharmaceutical Company Limited
    • 13.4.9.1. Overview
    • 13.4.9.2. Product and Technology Portfolio
    • 13.4.9.3. Production Footprint
    • 13.4.9.4. Sales Footprint
    • 13.4.9.5. Channel Footprint
    • 13.4.9.6. Strategy
      • 13.4.9.6.1. Marketing Strategy
      • 13.4.9.6.2. Product Strategy
      • 13.4.9.6.3. Channel Strategy
  • 13.4.10. Sunovion Pharmaceuticals, Inc.
    • 13.4.10.1. Overview
    • 13.4.10.2. Product and Technology Portfolio
    • 13.4.10.3. Production Footprint
    • 13.4.10.4. Sales Footprint
    • 13.4.10.5. Channel Footprint
    • 13.4.10.6. Strategy
      • 13.4.10.6.1. Marketing Strategy
      • 13.4.10.6.2. Product Strategy
      • 13.4.10.6.3. Channel Strategy

14. Global Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Region

• 14.1. Introduction/Key Findings
• 14.2. Historical Market Size (US$ Bn)Trend Analysis By Region, 2020 - 2024
• 14.3. Market Size (US$ Bn) Forecast By Region, 2025 - 2032
  • 14.3.1. North America
  • 14.3.2. Latin America
  • 14.3.3. Europe
  • 14.3.4. Asia Pacific Excluding China
  • 14.3.5. China
  • 14.3.6. Middle East & Africa
• 14.4. Market Attractiveness Analysis By Region

15. Global Insomnia Treatment Analysis 2020 - 2024 and Forecast 2025 - 2032, By Drug Type

• 15.1. Introduction/Key Findings
• 15.2. Historical Market Size (US$ Bn) Trend Analysis By Drug Type, 2020 - 2024
  • 15.2.1. OTC Drugs
    • 15.2.1.1. OTC Sleep Aids
    • 15.2.1.2. OTC Sleep Supplements
  • 15.2.2. Prescription Drugs
• 15.3. Market Size (US$ Bn) Forecast By Drug Type, 2025 - 2032
• 15.4. Market Attractiveness Analysis By Drug Type

16. Global Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Distribution Channel

• 16.1. Introduction/Key Findings
• 16.2. Historical Market Size (US$ Bn) Trend Analysis By Distribution Channel, 2020 - 2024
  • 16.2.1. Hospital Pharmacies
  • 16.2.2. Retail Pharmacies
  • 16.2.3. e commerce
  • 16.2.4. Drug Stores
  • 16.2.5. Others
• 16.3. Market Size (US$ Bn) Forecast By Distribution Channel, 2025 - 2032
• 16.4. Market Attractiveness Analysis By Distribution Channel

17. Global Insomnia Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

• 17.1. Market Value Share Analysis
• 17.2. Y-o-Y Growth Analysis
• 17.3. Absolute $ Opportunity

18. Research Methodology